Publication Date:
2011-01-14
Description:
beta-adrenergic receptors (betaARs) are G-protein-coupled receptors (GPCRs) that activate intracellular G proteins upon binding catecholamine agonist ligands such as adrenaline and noradrenaline. Synthetic ligands have been developed that either activate or inhibit betaARs for the treatment of asthma, hypertension or cardiac dysfunction. These ligands are classified as either full agonists, partial agonists or antagonists, depending on whether the cellular response is similar to that of the native ligand, reduced or inhibited, respectively. However, the structural basis for these different ligand efficacies is unknown. Here we present four crystal structures of the thermostabilized turkey (Meleagris gallopavo) beta(1)-adrenergic receptor (beta(1)AR-m23) bound to the full agonists carmoterol and isoprenaline and the partial agonists salbutamol and dobutamine. In each case, agonist binding induces a 1 A contraction of the catecholamine-binding pocket relative to the antagonist bound receptor. Full agonists can form hydrogen bonds with two conserved serine residues in transmembrane helix 5 (Ser(5.42) and Ser(5.46)), but partial agonists only interact with Ser(5.42) (superscripts refer to Ballesteros-Weinstein numbering). The structures provide an understanding of the pharmacological differences between different ligand classes, illuminating how GPCRs function and providing a solid foundation for the structure-based design of novel ligands with predictable efficacies.〈br /〉〈br /〉〈a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3023143/" target="_blank"〉〈img src="https://static.pubmed.gov/portal/portal3rc.fcgi/4089621/img/3977009" border="0"〉〈/a〉 〈a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3023143/" target="_blank"〉This paper as free author manuscript - peer-reviewed and accepted for publication〈/a〉〈br /〉〈br /〉〈span class="detail_caption"〉Notes: 〈/span〉Warne, Tony -- Moukhametzianov, Rouslan -- Baker, Jillian G -- Nehme, Rony -- Edwards, Patricia C -- Leslie, Andrew G W -- Schertler, Gebhard F X -- Tate, Christopher G -- BB/G003653/1/Biotechnology and Biological Sciences Research Council/United Kingdom -- MC_U105184325/Medical Research Council/United Kingdom -- MC_U105197215/Medical Research Council/United Kingdom -- U.1051.04.034/Medical Research Council/United Kingdom -- Medical Research Council/United Kingdom -- Wellcome Trust/United Kingdom -- England -- Nature. 2011 Jan 13;469(7329):241-4. doi: 10.1038/nature09746.〈br /〉〈span class="detail_caption"〉Author address: 〈/span〉MRC Laboratory of Molecular Biology, Hills Road, Cambridge CB2 0QH, UK.〈br /〉〈span class="detail_caption"〉Record origin:〈/span〉 〈a href="http://www.ncbi.nlm.nih.gov/pubmed/21228877" target="_blank"〉PubMed〈/a〉
Keywords:
Adrenergic beta-1 Receptor Agonists/*chemistry/metabolism/*pharmacology
;
Adrenergic beta-1 Receptor Antagonists/*chemistry/metabolism/*pharmacology
;
Albuterol/chemistry/metabolism/pharmacology
;
Amphetamines/chemistry/metabolism/pharmacology
;
Animals
;
Binding Sites
;
Catecholamines/metabolism
;
Crystallography, X-Ray
;
Dobutamine/chemistry/metabolism/pharmacology
;
Drug Design
;
*Drug Partial Agonism
;
Hydrogen Bonding
;
Hydroxyquinolines/chemistry/metabolism/pharmacology
;
Isoproterenol/chemistry/metabolism/pharmacology
;
Ligands
;
Models, Molecular
;
Protein Conformation
;
Protein Stability/drug effects
;
Receptors, Adrenergic, beta-1/*chemistry/*metabolism
;
Serine/chemistry/metabolism
;
Structure-Activity Relationship
;
Turkeys
Print ISSN:
0028-0836
Electronic ISSN:
1476-4687
Topics:
Biology
,
Chemistry and Pharmacology
,
Medicine
,
Natural Sciences in General
,
Physics
Permalink
